Talk Liver To Me: MASLD and HFpEF: Do We Need a Shared Treatment Strategy?

Wednesday, July 8

Time shown in-04:00 America, New York

Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF) are increasingly recognised as manifestations of a shared cardiometabolic disorder. Driven by overlapping risk factors such as obesity and insulin resistance, these conditions frequently coexist and may interact through liver–heart crosstalk. Despite this, they are typically managed separately, with limited disease-specific therapies and suboptimal outcomes. In this podcast, we explore whether a more integrated approach could improve diagnosis, risk stratification, and treatment. With Cyrielle Caussy (Host), Zannad Faiez (Faculty) and Pinelopi Manousou (Faculty)

Add to Calendar 2026/07/08 00:00:00 2026/07/08 23:59:59 Talk Liver To Me: MASLD and HFpEF: Do We Need a Shared Treatment Strategy? Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF) are increasingly recognised as manifestations of a shared cardiometabolic disorder. Driven by overlapping risk factors such as obesity and insulin resistance, these conditions frequently coexist and may interact through liver–heart crosstalk. Despite this, they are typically managed separately, with limited disease-specific therapies and suboptimal outcomes. In this podcast, we explore whether a more integrated approach could improve diagnosis, risk stratification, and treatment. With Cyrielle Caussy (Host), Zannad Faiez (Faculty) and Pinelopi Manousou (Faculty) https://easl.eu/event/masld-and-hfpef-do-we-need-a-shared-treatment-strategy/ true MM/DD/YYYY 10080 OPAQUE aKgrvzPIezYAnRajPmcy106622

https://easl.eu/event/masld-and-hfpef-do-we-need-a-shared-treatment-strategy/

EASL, easloffice@easloffice.eu

Link: